FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 10/2024”.
The Monitor is a month-to-month revealed overview of enterprise capital traits within the US Healthcare & Life Sciences sector.
As of the top of October 2024 we recognized the next present VC traits in the USA:
- Complete Healthcare & Life Sciences funding reached EUR 7,381m
- Biotech/Pharma acquired 60% of the entire funding quantity (EUR 4,442m) with oncology being the main indication (44%)
- In October, Nelly (Germany) secured the very best transaction quantity with EUR 100m, adopted by Purespring Therapeutics (United Kingdom) with EUR 95m and AgomAb (Belgium) with EUR 89m
- Common Atlantic (United States) is essentially the most lively investor (by deal quantity in 2024), adopted by European Innovation Council Fund (Belgium) and Forbion (Netherlands)
To entry the total report, please click on right here.
By Mathias Klozenbücher und Johannes Hyperlink